A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations

被引：0

作者：

Aftimos, Philippe ^{[1
]}

Oliveira, Mafalda ^{[2
]}

Punie, Kevin ^{[3
]}

Boni, Valentina ^{[4
]}

Hamilton, Erika ^{[5
]}

Gucalp, Ayca ^{[6
]}

Shah, Payal ^{[7
]}

Mina, Lida ^{[8
]}

Sharma, Priyanka ^{[9
]}

Bauman, Lisa ^{[10
]}

Campeau, Eric ^{[11
]}

Attwell, Sarah ^{[11
]}

Snyder, Margo ^{[10
]}

Norek, Karen ^{[11
]}

Czibere, Akos ^{[12
]}

Yu, Yanke ^{[13
]}

Silverman, Michael H. ^{[10
]}

Lakhotia, Sanjay ^{[10
]}

Domchek, Susan ^{[7
]}

Litton, Jennifer ^{[14
]}

Robson, Mark ^{[6
]}

机构：

[1] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[2] Vall dHebron Inst Oncol, Barcelona, Spain

[3] UZ Leuven, Leuven, Belgium

[4] START, Madrid, Spain

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[8] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[9] Univ Kansas, Ctr Canc, Westwood, KS USA

[10] Zenith Epigenet, San Francisco, CA USA

[11] Zenith Epigenet, Calgary, AB, Canada

[12] Pfizer, Cambridge, MA USA

[13] Pfizer, La Jolla, CA USA

[14] Univ Texas MD Anderson, Houston, TX USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS11-10

引用

页数：1

共 50 条

[31] A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Karthik Ramasamy
Ajay Nooka
Hang Quach
Myo Htut
Rakesh Popat
Michaela Liedtke
Sascha A. Tuchman
Jacob Laubach
Cristina Gasparetto
Asher Chanan-Khan
Mark Hertzberg
Mark deMario
Eveline Nueesch
Evelyne Chesne
Izolda Franjkovic
Katharina Lechner
Martin Kornacker
Hearn Jay Cho
Blood Cancer Journal, 11
[32] Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
Marbach, Daniel
Brouer-Visser, Jurriaan
Brennan, Laura
Wilson, Sabine
Davydov, Iakov I.
Staedler, Nicolas
Duarte, Jose
Quetglas, Iris Martinez
Nueesch, Eveline
Canamero, Marta
Chesne, Evelyne
Au-Yeung, George
Hamilton, Erika
Lheureux, Stephanie
Richardson, Debra L.
Spanggaard, Iben
Gomes, Bruno
Franjkovic, Izolda
Demario, Mark
Kornacker, Martin
Lechner, Katharina
BMC CANCER, 2025, 25 (01)
[33] Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.
Gordon, Michael S.
Carvajal, Richard D.
Spira, Alexander I.
Huang, Marilyn
Watkins, Paul
Powell, Ben
Inokuchi, Kerry
Sterba, Michael
Matusow, Bernice
Hope, Chelsea
Halladay, Jason
Zhang, Chao
Walling, Jacqueline M.
Tsiatis, Athanasios C.
Patnaik, Amita
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component.
Colman, Howard
Mott, Frank
Spira, Alexander I.
Johnson, Theodore S.
Zakharia, Yousef
Vahanian, Nicholas N.
Link, Charles J.
Kennedy, Eugene Paul
Sadek, Ramses F.
Munn, David
Rixe, Olivier
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[35] Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
Villalobos, Victor Manuel
Redondo, Andres
Van Tine, Brian Andrew
Schwartz, Gary K.
Dickson, Mark Andrew
Chmielowski, Bartosz
Peterson, Patrick
Cronier, Damien
Wright, Jennifer A.
Attia, Steven
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[36] FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: A phase 1B dose-expansion study
Gu, Junjie
Mao, Lili
Guo, Jun
Jiang, Yu
Zhu, Lingjun
Zhang, Xiaoshi
Yan, Wangjun
Chen, Yu
Tan, Chang
Zhu, Weiyou
Zhang, Jian
Liu, Jie
Lin, Jing
Wu, Zhuli
Wang, Xingli
Yang, Yuchen
Li, Ben
Si, Lu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia
Prebet, Thomas
Goldberg, Aaron D.
Jurcic, Joseph G.
Khaled, Samer
Dail, Monique
Feng, Yuning
Green, Cherie
Li, Chunze
Ma, Connie
Medeiros, Bruno C.
Yan, Mark
Grunwald, Michael R.
LEUKEMIA & LYMPHOMA, 2022, 63 (09) : 2180 - 2188
[38] Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
Dickinson, Michael
Briones, Javier
Herrera, Alex F.
Gonzalez-Barca, Eva
Ghosh, Nilanjan
Cordoba, Raul
Rutherford, Sarah C.
Bournazou, Eirini
Labriola-Tompkins, Emily
Franjkovic, Izolda
Chesne, Evelyne
Brouwer-Visser, Jurriaan
Lechner, Katharina
Brennan, Barbara
Nueesch, Eveline
DeMario, Mark
Ruettinger, Dominik
Kornacker, Martin
Hutchings, Martin
BLOOD ADVANCES, 2021, 5 (22) : 4762 - 4770
[39] A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Hong, David
Rasco, Drew
Veeder, Michael
Luke, Jason J.
Chandler, Jason
Balmanoukian, Ani
George, Thomas J.
Munster, Pamela
Berlin, Jordan D.
Gutierrez, Martin
Mita, Alain
Wakelee, Heather
Samakoglu, Selda
Guan, Shanhong
Dimery, Isaiah
Graef, Thorsten
Borazanci, Erkut
ONCOLOGY, 2019, 97 (02) : 102 - 111
[40] Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer
Iwase, Toshiaki
Damodaran, Senthil
Marx, Angela
Meric-Bernstam, Funda
Tripathy, Debashish
Barcenas, Carlos Hernando
Lee, Jangsoon
Ueno, Naoto Tada
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →